← Back to Treatments
🏅 FDA Orphan Designation

Astagraf XL

tacrolimus extended-release capsules

Manufacturer: Astellas Pharma Global Development, Inc.

Indicated for:
Recurrent hepatitis C virus induced liver disease in liver transplant recipientsOrphanOBSOLETE: Rejection after corneal transplantation
⚠️

Black Box Warning (Boxed Warning)

A Boxed Warning is the FDA's strongest safety warning — it indicates serious or life-threatening risks identified during clinical trials or post-market surveillance. It does not mean the medication is unsafe for all patients; your prescriber weighs these risks against the benefits for your specific situation. Source: FDA-approved prescribing information.

View full prescribing information on DailyMed (NLM) ↗

FDA-Approved Indications (2)

prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients.

indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants

Population: adult and pediatric patients who can swallow capsules intact

Indications & Usage

1 INDICATIONS AND USAGE ASTAGRAF XL ® is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact [see Use in Specific Populations ( 8.4 ) and Clinical Studies ( 14.1 ), ( 14.2 )]. ASTAGRAF XL is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact. ( 1 , 8.4 , 14.1 , 14.2 )

💙 Support Programs

View all →
ASTAGRAF XL
Astellas
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.